Einhorn

FONTAINEBLEAU LAS VEGAS TEAMS WITH DAVID GRUTMAN'S GROOT HOSPITALITY TO BRING ICONIC LIV AND LIV BEACH, KOMODO AND PAPI STEAK TO THE STRIP

Retrieved on: 
Wednesday, September 20, 2023
Komodo, Music, Partnership, Food, LIV, Investment, Tomahawk, Einhorn, David Rockwell, Restaurant, Groot, David Grutman, Rolling Stone, EDM, Wine, Las Vegas Strip, Hotel, Nightclub, Fontainebleau Las Vegas, Fontainebleau Miami Beach

LAS VEGAS, Sept. 20, 2023 /PRNewswire/ -- Fontainebleau Las Vegas, the globally anticipated luxury destination brought to life by Fontainebleau Development, has partnered with hospitality entrepreneur David Grutman of Groot Hospitality to bring the nightclub LIV and world-renown restaurants Komodo and Papi Steak to the property when it opens its doors to the world in December 2023, pending regulatory approvals. Additionally, Fontainebleau Las Vegas and Grutman will debut an all-new dayclub concept, LIV BEACH, in Spring 2024, just in time for pool season.

Key Points: 
  • Additionally, Fontainebleau Las Vegas and Grutman will debut an all-new dayclub concept, LIV BEACH, in Spring 2024, just in time for pool season.
  • Both Komodo and Papi Steak will be among the 36 first-to-market food and beverage concepts opening at Fontainebleau Las Vegas.
  • The strategic partnership between Fontainebleau Las Vegas and Groot Hospitality blends the expertise of two industry-changing hospitality leaders.
  • Fontainebleau Las Vegas stands on nearly 25 acres adjacent to the Las Vegas Convention Center District on the Las Vegas Strip.

Predictive Oncology Appoints Biopharmaceutical Finance Veteran Mr. Andrew Einhorn to its Business Advisory Board

Retrieved on: 
Tuesday, June 27, 2023
GMP, Good, Oncology, Drug development, American University, New Jersey Society for the Prevention of Cruelty to Animals, PNC Financial Services, Intelligence, American Institute of Certified Public Accountants, Cognition, Certified Public Accountant, Accounting, Einhorn, CLIA, Good manufacturing practice, Machine learning, Drug discovery, CFO, Therapy, American Institute, Pharmaceutical industry, Management

EAGAN, Minn., June 27, 2023 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI), a science-driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive biorepository of tumor samples, Clinical Laboratory Improvement Amendments (CLIA) laboratory and Good Manufacturing Practices (GMP) facility, to accelerate oncology drug discovery and enable drug development, today announced the appointment of biopharmaceutical finance veteran Mr. Andrew Einhorn to its Business Advisory Board.

Key Points: 
  • EAGAN, Minn., June 27, 2023 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI), a science-driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive biorepository of tumor samples, Clinical Laboratory Improvement Amendments (CLIA) laboratory and Good Manufacturing Practices (GMP) facility, to accelerate oncology drug discovery and enable drug development, today announced the appointment of biopharmaceutical finance veteran Mr. Andrew Einhorn to its Business Advisory Board.
  • “Andrew Einhorn brings a wealth of senior financial leadership experience in the biopharmaceutical industry to our Business Advisory Board, and I am very pleased that he has agreed to join,” said Raymond F. Vennare, Chief Executive Officer of Predictive Oncology.
  • Mr. Einhorn is a former certified public accountant licensed by the American Institute of Certified Public Accountants and the New Jersey Society of CPAs.
  • He is a graduate of The American University with a degree in finance and accounting.